Patents, Payment, Science: Triple Challenge To Pharmacogenetic Innovation
This article was originally published in The Gray Sheet
Talk that pharmacogenetics and its role in personalized medicine is the "next big thing" in healthcare is nothing new; but it is becoming clear that the path to widespread practical use of the science will be longer than some expected
You may also be interested in...
Though the promise of personalized medicine has been widely touted, firms focusing on targeted therapies and companion diagnostics are not getting much bang for their buck - yet
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.